- Investing Ideas
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
12
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
12 companies
CorMedix
Market Cap: US$600.9m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.64
7D
-11.2%
1Y
-35.2%
Protalix BioTherapeutics
Market Cap: US$185.3m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.35
7D
8.8%
1Y
58.8%
Rigel Pharmaceuticals
Market Cap: US$715.8m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$39.04
7D
9.3%
1Y
108.4%
Aurinia Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$16.79
7D
-6.1%
1Y
124.5%
ACADIA Pharmaceuticals
Market Cap: US$4.3b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$25.20
7D
14.1%
1Y
16.8%
Medpace Holdings
Market Cap: US$15.3b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$534.72
7D
12.9%
1Y
66.5%
TG Therapeutics
Market Cap: US$7.9b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$55.72
7D
2.4%
1Y
54.8%
Exelixis
Market Cap: US$13.8b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$54.28
7D
5.7%
1Y
23.2%
Catalyst Pharmaceuticals
Market Cap: US$3.9b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.46
7D
0.2%
1Y
48.5%
Eli Lilly
Market Cap: US$1.1t
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$1,229.93
7D
11.6%
1Y
57.8%
Earth Science Tech
Market Cap: US$46.1m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.16
7D
-10.0%
1Y
-15.8%
CapForce
Market Cap: US$111.5m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
CFOR
US$18.00
7D
414.3%
1Y
276.6%